S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:ERAS

Erasca (ERAS) Stock Forecast, Price & News

$1.97
-0.05 (-2.48%)
(As of 09/29/2023 ET)
Compare
Today's Range
$1.96
$2.05
50-Day Range
$1.97
$2.91
52-Week Range
$1.96
$9.25
Volume
400,640 shs
Average Volume
581,262 shs
Market Capitalization
$297.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Erasca MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
458.4% Upside
$11.00 Price Target
Short Interest
Bearish
9.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.78mentions of Erasca in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.03) to ($1.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

462nd out of 972 stocks

Pharmaceutical Preparations Industry

207th out of 445 stocks


ERAS stock logo

About Erasca (NASDAQ:ERAS) Stock

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

ERAS Price History

ERAS Stock News Headlines

Erasca to Present at the Cantor Global Healthcare Conference
Erasca, Inc. (ERAS)
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company
Decades of pent-up demand for this "first-ever" treatment could give you WINDFALL PROFITS... Click here to learn more >>>
Erasca (ERAS) Receives a Buy from Mizuho Securities
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Erasca: Trading Near Cash Value
Erasca's ERAS-801 Gets FDA's Orphan Drug Status
Jonathan Lim Spends US$275k On Erasca Stock
Jonathan Lim Spends US$275k On Erasca Stock \
Erasca Insider Trades Send a Signal
Analyst Expectations for Erasca's Future
Erasca (ERAS) Gets a Buy from Goldman Sachs
See More Headlines
Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Company Calendar

Last Earnings
8/10/2023
Today
9/30/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ERAS
Fax
N/A
Employees
129
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+458.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-242,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.37 per share

Miscellaneous

Free Float
106,032,000
Market Cap
$297.55 million
Optionable
Not Optionable
Beta
1.10
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Jonathan E. Lim M.D. (Age 51)
    Co-Founder, Chairman & CEO
    Comp: $940.32k
  • Dr. David M. Chacko M.D. (Age 39)
    CFO & Chief Bus. Officer
    Comp: $616.76k
  • Dr. Michael D. Varney Ph.D. (Age 65)
    Chairman of R&D, Scientific Advisory Board Member and Director
    Comp: $83.26k
  • Dr. Nik Chetwyn Ph.D.
    Chief Operating Officer
  • Mr. Ebun S. Garner J.D. (Age 51)
    Esq., Gen. Counsel & Corp. Sec.
  • Dr. Lisa Tesvich-Bonora Ph.D.
    Chief People Officer
  • Mr. Brian L. Baker CPA (Age 56)
    M.S., MS, CPA, Sr. VP of Fin.
  • Ms. Chandra D. Lovejoy M.S. (Age 52)
    Chief Regulatory Affairs Officer
  • Dr. Robert Shoemaker Ph.D. (Age 42)
    Sr. VP of Research
  • Dr. Shannon R. Morris M.D. (Age 53)
    Ph.D., Chief Medical Officer













ERAS Stock - Frequently Asked Questions

Should I buy or sell Erasca stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ERAS shares.
View ERAS analyst ratings
or view top-rated stocks.

What is Erasca's stock price forecast for 2023?

3 Wall Street analysts have issued 12 month price targets for Erasca's stock. Their ERAS share price forecasts range from $8.00 to $15.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 458.4% from the stock's current price.
View analysts price targets for ERAS
or view top-rated stocks among Wall Street analysts.

How have ERAS shares performed in 2023?

Erasca's stock was trading at $4.31 on January 1st, 2023. Since then, ERAS stock has decreased by 54.3% and is now trading at $1.97.
View the best growth stocks for 2023 here
.

Are investors shorting Erasca?

Erasca saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 8,430,000 shares, a decrease of 5.5% from the August 31st total of 8,920,000 shares. Based on an average daily volume of 508,500 shares, the short-interest ratio is currently 16.6 days. Approximately 9.1% of the company's shares are short sold.
View Erasca's Short Interest
.

When is Erasca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ERAS earnings forecast
.

How were Erasca's earnings last quarter?

Erasca, Inc. (NASDAQ:ERAS) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06.

What ETF holds Erasca's stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 40,125 shares of ERAS stock, representing 0.90% of its portfolio.

When did Erasca IPO?

(ERAS) raised $262 million in an initial public offering on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.

What is Erasca's stock symbol?

Erasca trades on the NASDAQ under the ticker symbol "ERAS."

How do I buy shares of Erasca?

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Erasca's stock price today?

One share of ERAS stock can currently be purchased for approximately $1.97.

How much money does Erasca make?

Erasca (NASDAQ:ERAS) has a market capitalization of $297.55 million. The company earns $-242,800,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis.

How many employees does Erasca have?

The company employs 129 workers across the globe.

How can I contact Erasca?

The official website for the company is www.erasca.com. The company can be reached via phone at 858-465-6511 or via email at ir@erasca.com.

This page (NASDAQ:ERAS) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -